secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001193125-25-146905
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai LifeSciences appoints Rajesh Asarpota as CFO effective June 30, 2025, succeeding Kevin Herde
--------------------------------------------------------------------------------

- Rajesh Asarpota appointed EVP and CFO effective June 30, 2025; Kevin Herde transitions to advisory role through Jan 31, 2026.
- Asarpota receives $550k base salary, 70% target bonus, $200k cash sign-on bonus, and equity awards (333,333 options, 500k RSUs, 750k PSUs).
- Previous CFO Kevin Herde entitled to severance payments per May 2023 employment agreement upon signing separation agreement.
- Company not reaffirming or withdrawing FY2025 guidance; will review during Q2 2025 earnings call in August.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000119312525146905/0001193125-25-146905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000119312525146905/d32006d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-146905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer